You are here

  • Home
  • Archive
  • Volume 78, Issue 4
  • Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke

Article Text

Article menu

Download PDFPDF

Correspondence response
Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke
Free
  1. Fabrizio Cantini1,
  2. Maurizio Benucci2
  1. 1 Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy
  2. 2 Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S Giovanni di Dio Hospital, Florence, Italy
  1. Correspondence to Dr Fabrizio Cantini, Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, 59100 Prato PO, Italy; fbrzcantini{at}gmail.com

https://doi.org/10.1136/annrheumdis-2018-213044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We are grateful to Scherlinger and Schaeverbeke for their reply to our letter.1

    We would like to remind that in our letter we raised several concerns regarding the low grade of evidence supporting recommendation 6 on the switching procedure, as reported in the recently published recommendations for the use of biosimilars in rheumatology practice.2 3 We believe that international recommendations should be based on solid bases, and, as underlined in our letter, by analysis of the existing literature, the evidence of such strategy in terms of efficacy, safety, retention rate and also economic advantages is poor. In particular, the colleagues focus their remarks on reduced bio-etanercept …

    View Full Text

    Linked Articles